

Elliott Chandler Dasenbrook

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2304214/publications.pdf>

Version: 2024-02-01

24
papers

1,603
citations

516215

16
h-index

642321

23
g-index

24
all docs

24
docs citations

24
times ranked

1930
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhaled Corticosteroids in Patients With Stable Chronic Obstructive Pulmonary Disease. JAMA - Journal of the American Medical Association, 2008, 300, 2407.	3.8	315
2	Association Between Respiratory Tract Methicillin-Resistant <i>Staphylococcus aureus</i> and Survival in Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2010, 303, 2386.	3.8	312
3	Persistent Methicillin-resistant <i>Staphylococcus aureus</i> and Rate of FEV ₁ Decline in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 814-821.	2.5	294
4	Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant <i>Staphylococcus aureus</i> , Gram-Negative Bacteria, and Multiple Infections. Annals of the American Thoracic Society, 2014, 11, 1120-1129.	1.5	175
5	Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis. Journal of Cystic Fibrosis, 2010, 9, 110-116.	0.3	115
6	Antibiotic Management of Lung Infections in Cystic Fibrosis. II. Nontuberculous Mycobacteria, Anaerobic Bacteria, and Fungi. Annals of the American Thoracic Society, 2014, 11, 1298-1306.	1.5	75
7	Higher PEEP in Patients With Acute Lung Injury: A Systematic Review and Meta-Analysis. Respiratory Care, 2011, 56, 568-575.	0.8	40
8	Utilization of antibiotics for methicillin-resistant <i>Staphylococcus aureus</i> infection in cystic fibrosis. Pediatric Pulmonology, 2015, 50, 552-559.	1.0	39
9	Update on methicillin-resistant <i>Staphylococcus aureus</i> in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2011, 17, 437-441.	1.2	35
10	Eradication of persistent methicillin-resistant <i>Staphylococcus aureus</i> infection in cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 357-363.	0.3	35
11	Effect of Including Important Clinical Variables on Accuracy of the Lung Allocation Score for Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1013-1021.	2.5	28
12	Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. Journal of Cystic Fibrosis, 2015, 14, 370-375.	0.3	24
13	Eradication strategy for persistent methicillin-resistant <i>Staphylococcus aureus</i> infection in individuals with cystic fibrosis—the PMEP trial: study protocol for a randomized controlled trial. Trials, 2014, 15, 223.	0.7	21
14	Cystic fibrosis patient registries: A valuable source for clinical research. Journal of Cystic Fibrosis, 2018, 17, 433-440.	0.3	21
15	Impact of Socioeconomic Position on Access to the U.S. Lung Transplant Waiting List in a Matched Cystic Fibrosis Cohort. Annals of the American Thoracic Society, 2020, 17, 1384-1392.	1.5	19
16	Normalized T1 Magnetic Resonance Imaging for Assessment of Regional Lung Function in Adult Cystic Fibrosis Patients - A Cross-Sectional Study. PLoS ONE, 2013, 8, e73286.	1.1	18
17	Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients. Journal of Cystic Fibrosis, 2017, 16, 283-290.	0.3	15
18	Inhaled Hypertonic Saline in Infants and Young Children With Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2012, 307, 2316-7.	3.8	8

#	ARTICLE	IF	CITATIONS
19	Isoflurane and ketamine anesthesia have different effects on ventilatory pattern variability in rats. <i>Respiratory Physiology and Neurobiology</i> , 2013, 185, 659-664.	0.7	8
20	Cystic fibrosis and survival in patients with advanced lung disease. <i>BMJ: British Medical Journal</i> , 2011, 342, d726-d726.	2.4	2
21	Antibiotic Use and Stewardship in Cystic Fibrosis: A Review for Noncystic Fibrosis Providers. <i>Clinical Pulmonary Medicine</i> , 2020, 27, 131-138.	0.3	2
22	Rapid lung function decline in adults with early-stage cystic fibrosis lung disease. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 527-533.	0.3	1
23	Dyschromic Nails, Exertional Dyspnea, and Lower Extremity Edema. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1992.	3.8	1
24	The Impact of MRSA on Lung Function in Patients with Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 735-735.	2.5	0